Company Filing History:
Years Active: 1997-1999
Title: Innovations of Ann Pole in Mycoplasma Research
Introduction
Ann Pole is a distinguished inventor based in Salt Lake City, Utah. She has made significant contributions to the field of microbiology, particularly in the study of Mycoplasma arthritidis. With two patents to her name, her work has implications for understanding autoimmune diseases and developing potential immunization strategies.
Latest Patents
Ann Pole's latest patents focus on a method of purifying Mycoplasma arthritidis T-cell mitogen (MAM) to achieve electrophoretic and sequence homogeneity. This innovative method has allowed for the determination of the sequence of the N-terminal 54 amino acids of MAM. A synthetic peptide consisting of amino acids 15-32 was found to inhibit MAM-induced cell proliferation in vitro. The MAM gene was sequenced and identified on a 1107 bp DNA fragment, revealing a primary translation product that includes a 39 amino acid signal sequence and a 213 amino acid mature MAM with a molecular weight of 25,294. Comparisons of the amino acid sequence of MAM to bacterial and murine tumor virus superantigens have shown regions of conservative sequence homology, which includes the region capable of inhibiting cell proliferation. Additionally, sequence homologies to HIV and other retrovirus proteins were detected, leading to strategies for blocking or immunizing against certain diseases, including autoimmune diseases.
Career Highlights
Ann Pole is affiliated with the University of Utah Research Foundation, where she continues her research and innovation in microbiology. Her work has garnered attention for its potential applications in medical science and disease prevention.
Collaborations
She has collaborated with notable colleagues, including Barry C. Cole and Curtis L. Atkin, contributing to a rich environment of research and innovation.
Conclusion
Ann Pole's contributions to the field of Mycoplasma research exemplify the impact of innovative thinking in science. Her patents and ongoing work continue to pave the way for advancements in understanding and treating autoimmune diseases.